[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"robot-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:robot-surgery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,69,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100618754","study-on-the-safety-and-efficacy-of-domestic-single-port-robot-assisted-metabolic-bariatric-surgery-100618754",false,"NCT07335731","Study on the Safety and Efficacy of Domestic Single-Port Robot-Assisted Metabolic Bariatric Surgery.","Inclusion Criteria:\n\n* ①Overweight or obese patients who meet the criteria for metabolic weight loss surgery, with a BMI ≥ 27.5 kg\u002Fm2; ② Patients who understand the purpose of the trial, voluntarily participate in the trial, and sign an informed consent form.\n\nExclusion Criteria:\n\n* ① Patients who cannot tolerate general anesthesia, such as those with severe heart, lung, or liver dysfunction; ② Patients with severe coagulation disorders; ③ Pregnant patients; ④ Patients with concurrent tumors; ⑤ Patients with extensive and severe abdominal adhesions that prevent the establishment of pneumoperitoneum; ⑥ A BMI \\> 50 kg\u002Fm² is a relative contraindication; ⑦ Patients deemed unsuitable for participation in this trial by any other investigator.","ALL","18 Years","65 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to obtain short-term clinical results on the safety and efficacy of single-port robot-assisted metabolic weight loss surgery, and to provide further evidence for the clinical promotion of single-port robot systems.",[26,27],"Obesity","Robot Surgery","RECRUITING","2026-01-12",{"date":31,"type":32},"2026-01-13","ACTUAL",{"date":34,"type":32},"2025-07-10",{"date":36,"type":20},"2027-07-30",{"name":38,"class":39},"China-Japan Friendship Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100601337","robot-assisted-versus-open-lateral-pancreaticojejunostomy-for-the-treatment-of-symptomatic-chronic-pancreatitis-panacotta-100601337","NCT07109180","Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA)","Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA): a Multicenter Randomized Controlled Trial","PANACOTTA","Inclusion Criteria:\n\n* At least 18 years old\n* Indication for (extended or partial) lateral pancreaticojejunostomy as agreed during multidisciplinary team meeting based on symptomatic chronic pancreatitis (i.e. morphine dependent pain or recurrent acute flares of pancreatitis, at least 3 episodes per year) and a dilated pancreatic duct of ≥ 5 mm, with a non-enlarged pancreatic head \\\u003C 40 mm\n* Confirmed CP, according to the M-ANNHEIM diagnostic Criteria24\n* Eligible for both an robot-assisted and open approach\n* Obtained written informed consent\n\nExclusion Criteria:\n\n* Suspected or confirmed current pancreatic cancer\n* ASA classification ≥ 4\n* Other painful conditions aside from CP, with pain difficult to discriminate from CP pain\n* Prior pancreatic surgery\n* Pregnancy",{"count":50,"type":20},28,[23],"PANACOTTA is a multicenter randomized controlled trial including patients with symptomatic chronic pancreatitis and a dilated main pancreatic duct to either robot-assisted or open lateral pancreaticojejunostomy. The PANACOTTA trial will assess the post-operative quality of recovery following robot-assisted versus open lateral pancreaticojejunostomy.",[54,55,56,57,27,58,59],"Chronic Pancreatitis","Surgery","Minimally Invasive Surgical Technique","Robot Surgica","Minimally Invasive Surgery","Pancreaticojunostomy","2025-07-31",{"date":62,"type":32},"2025-08-07",{"date":64,"type":32},"2025-04-16",{"date":66,"type":20},"2026-12-31",{"name":68,"class":39},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100590873","efficacy-and-safety-of-robot-assisted-endoscopic-submucosal-dissection-for-colorectal-neoplasm-100590873","NCT06973083","Efficacy and Safety of Robot-assisted Endoscopic Submucosal Dissection for Colorectal Neoplasm","Efficacy and Safety of Robot-assisted Endoscopic Submucosal Dissection for Colorectal Neoplasm: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Patients aged 18-85.\n* Patients with pathologically verified colorectal neoplasms scheduled to undergo ESD.\n\nExclusion Criteria:\n\n* Patients have lesions with confirmed or potential deep submucosal invasion or lymph node metastasis or other conditions that are not suitable for endoscopic therapy.\n* Patients with severe underlying diseases precluding endotracheal intubation, general anesthesia, or surgery.\n* Patients have a history of colorectal malignancy with previous radiotherapy or operative treatment leading to changes in colorectal structure.\n* Patients have lesions with local recurrence after endoscopic resection.\n* Patients unable to obtain informed consent.","85 Years",{"count":78,"type":20},104,[23],"The objective of this study is to investigate the role of the flexible auxiliary single-arm transluminal endoscopic robot (FASTER) system in colorectal endoscopic submucosal dissection (ESD) and to validate its superiority over conventional ESD in terms of reducing procedural difficulty, shortening procedure time, and enhancing procedural safety.\n\nThe main questions it aims to answer are:\n\nDoes the use of the FASTER system improve the dissection speed of the ESD procedure? Does the use of the FASTER system reduce the procedure and dissection time, improving the efficacy of the ESD procedure? Does the use of the FASTER system reduce the rate of perforation and hemorrhage, improving the safety of the ESD procedure? Researchers will compare FASTER-assisted ESD and conventional ESD to evaluate the safety and efficacy of the FASTER system.\n\nParticipants will:\n\nBe randomly assigned to the group with ESD using the traditional procedure or to the group with ESD assisted by the FASTER system.\n\nKeep a diary of their symptoms after the procedure. ESD has gained widespread acceptance as the standard method for treating early-stage gastrointestinal cancers. However, ESD is a technically demanding and intricate procedure that requires advanced proficiency of operators, with a heightened risk of complications such as hemorrhage and perforation. The inherent challenges of the colorectal ESD are further amplified by the thin mucosa, highly tortuous and flexible lumen, and occasional obstruction of lesions by mucosal folds, all of which collectively elevate both the procedural difficulty and the probability of postoperative complications. Adequate exposure of the submucosa layer through effective tissue traction is vital for the safe and effective performance of ESD. The FASTER system is designed to overcome this technical difficulty.",[27,82,83],"Endoscopic Submucosal Dissection (ESD)","Colorectal Neoplasms","NOT_YET_RECRUITING","2025-05-16",{"date":87,"type":32},"2025-05-21",{"date":89,"type":20},"2025-06-01",{"date":91,"type":20},"2026-12-30",{"name":93,"class":39},"Shandong University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":40},"100573597","safety-and-efficacy-of-traction-robot-assisted-endoscopic-submucosal-dissection-for-early-gastric-cancer-100573597","NCT06748352","Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer","Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer: a Pilot Randomized Controlled Study","Inclusion Criteria:\n\n* Patients aged 18-80.\n* Patients with pathologically verified high-grade intraepithelial neoplasia (HGIN) or intramucosal carcinoma of the stomach.\n\nExclusion Criteria:\n\n* Patients have lesions with confirmed or potential deep submucosal invasion or lymph node metastasis.\n* Patients with severe underlying diseases precluding endotracheal intubation, general anesthesia, or surgery.\n* Patients have a history of gastric malignancy with previous radiotherapy or operative treatment leading to changes in gastric structure.\n* Patients have lesions with local recurrence after endoscopic resection.\n* Patients unable to obtain informed consent.","80 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to investigate whether the flexible auxiliary single-arm transluminal endoscopic robot (FASTER) system can improve the safety of the endoscopic submucosal dissection (ESD). It will also evaluate the efficacy of the system, such as whether it could reduce the procedure time and so on. The main questions it aims to answer are:\n\nDoes the use of the FASTER system reduce the number of muscular injuries, improving the safety of the ESD procedure? Does the use of the FASTER system reduce the procedure and dissection time, improving the efficacy of the ESD procedure? Researchers will compare FASTER-assisted ESD and conventional ESD to evaluate the safety and efficacy of the FASTER system.\n\nParticipants will:\n\nBe randomly assigned to the group with ESD using the traditional procedure or to the group with ESD assisted by the FASTER system.\n\nKeep a diary of their symptoms after the procedure. ESD has gained widespread acceptance as the standard method for treating early-stage gastrointestinal cancers. Adequate exposure of the submucosa layer through effective tissue traction is vital for the safe and effective performance of ESD. The FASTER system is designed to overcome this technical difficulty.",[106,107,27],"Early Gastric Cancer","Endoscopic Submucosal Dissection","2024-12-21",{"date":110,"type":32},"2024-12-27",{"date":112,"type":20},"2024-12-30",{"date":114,"type":20},"2025-03-01",{"name":93,"class":39}]